Elisa Agostinetto: The Preferable-Effect trial is now out
Elisa Agostinetto, Medical Oncologist at the Brussels University Hospital, posted on X, about recent paper by Aniek E.M. Schouten et al., titled “Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial” published on Journal of Clinical Oncology.
Authors: Aniek E.M. Schouten, Anouk E. Hiensch, Geert W.J. Frederix, Evelyn M. Monninkhof, Martina E. Schmidt, Dorothea Clauss, Nadira Gunasekara, Jon Belloso, Mark Trevaskis, Helene Rundqvist, Joachim Wiskemann, Jana Müller, Maike G. Sweegers, Carlo Fremd, Renske Altena, Rhodé M. Bijlsma, Gabe Sonke, Ainhara Lahuerta, G. Bruce Mann, Prudence A. Francis, Gary Richardson, Wolfram Malter, Joanna Kufel-Grabowska, Elsken van der Wall, Neil K. Aaronson, Elzbieta Senkus, Ander Urruticoechea, Eva M. Zopf, Wilhelm Bloch, Martijn M. Stuiver, Yvonne Wengstrom, Karen Steindorf, Miriam P. van der Meulen, Anne M. May
“Following the results presented at SABCS23, the Preferable-Effect trial is now out in Journal of Clinical Oncology.
Exercise for patients with metastatic breast cancer improved quality of life, reduced costs, and is cost-effective.”
Dr. Elisa Agostinetto is a Clinical Research Fellow at the Jules Bordet Institute and a Medical Oncologist at the Brussels University Hospital. Specializing in breast cancer, her work focuses on advancing clinical oncology research and improving cancer treatment and patient care. Actively involved in professional societies such as ESMO, ASCO, and BSMO, Dr. Agostinetto serves as a Young Investigator in the EORTC Breast Cancer Working Group and is a Committee Member of the Young Cancer Professionals within the European Cancer Organization.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023